Evidence map›Paper›PMID 39482282›Full record

ArticlePsycho-oncology2024

Psychometric Properties of the Generalized Anxiety Disorder Scale (GAD-7) in Older Adults With Advanced Cancer.

Rebecca M Saracino, Lee A Kehoe, Michael B Sohn, Lu Wang, Supriya Mohile, Megan Wells, Karen Mustian, Gary Morrow, Thomas Bradley, Adedayo Onitilo and 2 more

Abstract readMulticenter Study
In one paragraph

Article in Psycho-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Adapting a mental health program for people with multiple myeloma and smouldering myeloma: a consumer-informed feasibility study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rebecca M SaracinoDepartment of Psychiatry and Behavioral Science, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0003-1093-7676
Lee A KehoeJames P. Wilmot Cancer Institute, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Michael B SohnDepartment of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Lu WangDepartment of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Supriya MohileJames P. Wilmot Cancer Institute, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Megan WellsJames P. Wilmot Cancer Institute, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Karen MustianJames P. Wilmot Cancer Institute, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Gary MorrowJames P. Wilmot Cancer Institute, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Thomas BradleyNorthwell Health, NCORP Northwell, RJ Zuckerberg Cancer Center, New Hyde Park, New York, USA.
Adedayo OnitiloWisconsin NCORP, Marshfield Clinic, Marshfield, Wisconsin, USA.ORCID 0000-0001-9185-0606
Jeffrey GiguereNCORP of the Carolinas, Prisma Health, Greenville, South Carolina, USA.
Kelly M McConnellDepartment of Psychiatry and Behavioral Science, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-2018-1860

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
URCC NCORP Research BaseUG1CA189961 · NCI · UNIVERSITY OF ROCHESTER · PI Michelle C Janelsins, KAREN M. MUSTIAN · 2014 to 2026
$67.7M
Understanding Treatment Tolerability in Older Patients with CancerU01CA233167 · NCI · UNIVERSITY OF ROCHESTER · PI MOHILE, SUPRIYA G. · 2018 to 2023
$3.5M
Reducing Chemotherapy Toxicity in Older AdultsR01CA177592 · NCI · UNIVERSITY OF ROCHESTER · PI MOHILE, SUPRIYA G. · 2013 to 2018
$3.0M
Clinical and Translational Cancer Control Research Training ProgramT32CA102618 · NCI · UNIVERSITY OF ROCHESTER · PI Michelle C Janelsins, Gary R Morrow · 2019 to 2026
$2.7M
Behavioral Activation for Depression in Older Adult Cancer Survivors: Pilot Randomized Control Trial and Implementation OutcomesK08CA252633 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SARACINO, REBECCA · 2021 to 2025
$902k
NCI NIH HHS K08 CA252633NCI NIH HHS L30 CA242702NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA177592NCI NIH HHS T32 CA102618NCI NIH HHS U01 CA233167NCI NIH HHS UG1 CA189961RRF Foundation for Aging Grant
6 · The paper itself

Abstract

objectivesOver half of new cancer diagnoses occur in patients aged 65 or older, with up to 40% experiencing anxiety. The American Society of Clinical Oncology recommends using the Generalized Anxiety Disorder Scale (GAD-7) for anxiety screening, but the GAD-7 psychometric properties in this population are unknown. This study examined the GAD-7's reliability, validity, and item parameters, comparing its utility with the GAD-2 in older adults with cancer.

methodsThis cross-sectional secondary analysis of a nationwide multi-site two-arm cluster randomized trial in older adults (≥ 70) with advanced cancer. The GAD-7 was administered at baseline. Properties were evaluated with Cronbach's α, Pearson correlation coefficients, and a 2-parameter logistic model. Logistic regression models compared the GAD-2 and GAD-7.

resultsThe sample included 718 participants (Mean age = 77, SD = 5) with mild anxiety (M = 3.74, SD = 4.74). Internal consistency was strong (Cronbach's alpha = 0.89) and item-total correlations ranged 0.53 to 0.78. Item 2 (Not being able to stop or control worrying) was the most discriminating and item 5 (Being so restless that it is hard to sit still) was least discriminating. Area Under the Curve (AUC) analyses demonstrated the GAD-2 had a 0.93-0.96 AUC.

conclusionsEstablishing the psychometric properties of anxiety screening measures is crucial in the older adults with cancer to maximize referral efficiency and accuracy. This study indicates that the GAD-7 is reliable and valid for older adults with cancer. Analyses suggest the GAD-2 may be as sufficient as the GAD-7 in identifying anxiety in older adults with cancer, thereby reducing assessment burden.

Indexed as

Anxiety DisordersNeoplasmsPsychometricsAgedAged, 80 and overAnxietyCross-Sectional StudiesFemaleHumansMalePsychiatric Status Rating ScalesReproducibility of Resultsadvanced canceragingcancergeneralized anxietygeriatric oncologyoncologypsychometrics

Identifiers

PMID39482282
PMCPMC11905212

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.